Review
Biochemistry & Molecular Biology
Jorrit M. Enserink, Pierre Chymkowitch
Summary: Cdk1 is a master regulator of the cell cycle, controlling progression through different phases. It also directly regulates RNA polymerase activity, which is important for protein synthesis and meeting cellular demands. This regulation promotes cell cycle entry.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Microbiology
Yanfei Zhang, Matteo Barberis
Summary: Coordination between cell cycle and metabolism is important for cell division and new cell construction. Cyclin-dependent kinases (Cdks) play a crucial role in this coordination, regulating cell division. This study reveals the possible impact of cell cycle mechanisms on cellular metabolism, finding that certain metabolic enzymes may be phosphorylated by Cdks, affecting their activities and metabolic regulation.
FRONTIERS IN MICROBIOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Pawel Lukasik, Michal Zaluski, Izabela Gutowska
Summary: Cyclin-dependent kinases are crucial in various cellular processes and their dysregulation can lead to diseases, making them potential drug targets.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Plant Sciences
Rui-Yi Yang, Jia-Yi Tan, Zhe Liu, Xiao-Ling Shen, Ying-Jie Hu
Summary: The natural lignan LAF from Arctium lappa Linne has been found to inhibit tumor cell growth in vitro and in vivo. However, its role in cell cycle regulation remains unknown.
PHARMACEUTICAL BIOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Marika A. V. Reinius, Elizabeth Smyth
Summary: The introduction of CKI inhibitors has been a major development in the treatment of advanced breast cancer, with potential applications beyond metastatic breast cancer treatment. Evidence suggests that these agents have impacts on cancer immunology and metabolism, expanding our understanding of their therapeutic effects. Challenges and opportunities in the 2020s, including treatment resistance and biomarker development, are anticipated in the continued research and application of CKIs.
EXPERT REVIEWS IN MOLECULAR MEDICINE
(2021)
Editorial Material
Chemistry, Medicinal
Mark Klein
Summary: Cyclin-dependent kinases (CDKs) have important roles in normal cells and can be targeted for cancer therapy. CDK4 inhibitors have been approved for advanced breast cancer treatment. However, the development of selective inhibitors for individual CDKs is challenging due to the highly conserved ATP-binding site.
Article
Microbiology
Juri Kim, Eun-Ah Park, Mee Young Shin, Soon-Jung Park
Summary: This study investigated the functional roles of Giardia lamblia CDKs (GlCDKs) and their cognate cyclins. Using morpholino-mediated knockdown and coimmunoprecipitation, the functions of GlCDK1 and GlCDK2 were distinguished. GlCDK1 with Glcyclin 3977 plays a crucial role in flagellum formation and cell cycle control of G. lamblia, while GlCDK2 with Glcyclin 22394/6584 is involved in cell cycle control.
MICROBIOLOGY SPECTRUM
(2023)
Review
Cell Biology
Aleksandra J. Pluta, Cecilia Studniarek, Shona Murphy, Chris J. Norbury
Summary: This article discusses the important roles of structurally related cyclin-dependent protein kinases (CDKs) in eukaryotic cell function, highlighting their roles in cell cycle regulation and transcriptional regulation, and the overlap between these processes.
WILEY INTERDISCIPLINARY REVIEWS-RNA
(2023)
Article
Oncology
Elena Garralda, Alison M. Schram, Philippe L. Bedard, Gary K. Schwartz, Eunice Yuen, Samuel C. McNeely, Silvia Ribeiro, Jason Cunningham, Yi Wang, Arantxa Urunuela, Xiaojian Xu, Patricia LoRusso
Summary: LY3405105 is a promising CDK7 inhibitor with good bioavailability and selectivity. However, the clinical trial showed limited efficacy and no plans for further development. The MTD of LY3405105 monotherapy was determined to be 20 mg QD.
Article
Cell Biology
Zongren Wan, Lixin Wang, Dan Yang, Pengling Li, Qing Liu, Baolan Wang
Summary: The study revealed that CKS2 is upregulated in NSCLC tissues and cells, promoting cell growth and cell cycle progression, while its knockdown suppresses tumorigenesis. CKS2 could potentially serve as a biomarker in NSCLC progression and prognosis.
Article
Immunology
Sandro Capellmann, Roland Sonntag, Herdit Schueler, Steffen K. Meurer, Lin Gan, Marlies Kauffmann, Katharina Horn, Hiltrud Koenigs-Werner, Ralf Weiskirchen, Christian Liedtke, Michael Huber
Summary: Mast cells (MCs) are heterogeneous immune cells with different protease repertoires and receptor expressions. A new cell line, PMC-306, derived from primary peritoneal MCs, can be used to study PMC function and tumorigenic processes associated with MC leukemia.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Cell Biology
Mohummad Aminur Rahman, Agnete S. T. Engelsen, Shahin Sarowar, Christian Bindesboll, Even Birkeland, Dorota Goplen, Maria L. L. Lotsberg, Stian Knappskog, Anne Simonsen, Martha Chekenya
Summary: The study found that bortezomib can enhance the efficacy of temozolomide by inhibiting autophagic flux, thereby increasing the treatment effect on glioblastoma and increasing the occurrence of cell apoptosis.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Pharmacology & Pharmacy
Yanting Zhou, Xiandeng Li, Peifang Luo, Huiting Chen, Yan Zhou, Xueting Zheng, Yuan Yin, Haoche Wei, Hongji Liu, Wen Xia, Mingsong Shi, Xiaoan Li
Summary: CDK4/6 is a crucial player in various cancers and a potential target for anticancer drugs. The interaction between abemaciclib and human CDK6 was studied, and C2231-A was identified as a promising candidate compound with significant inhibitory effects on human breast cancer cell lines.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Pawel Lukasik, Irena Baranowska-Bosiacka, Katarzyna Kulczycka, Izabela Gutowska
Summary: Recent studies have shown that small molecule drugs targeting CDK inhibitors have become attractive options for treating cancer and neurodegenerative disorders. Most CDK inhibitors target the ATP binding pocket, but the similarity in structure among CDK kinases makes achieving selectivity challenging. Therefore, inhibitors binding outside the ATP binding site have attracted great interest for their potential applications in the biomedical field.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Pharmacology & Pharmacy
Hanzhi Liang, Jintong Du, Reham M. Elhassan, Xuben Hou, Hao Fang
Summary: CDK7, a key player in the cell cycle and transcriptional regulation, is considered a promising therapeutic target for cancer treatment. CDK7 selective inhibitors, such as SY-5609 and CT7001, are in clinical development, but challenges including selectivity, side effects, and drug resistance still need to be addressed. Despite these challenges, ongoing clinical development and in-depth analysis of CDK7 inhibitors suggest they will become a promising approach for cancer treatment in the near future.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2021)
Article
Biochemistry & Molecular Biology
Marco Galasso, Carl Morrison, Linda Minotti, Fabio Corra, Carlotta Zerbinati, Chiara Agnoletto, Federica Baldassari, Matteo Fassan, Armando Bartolazzi, Andrea Vecchione, Gerard J. Nuovo, Gianpiero Di Leva, Stefania D'Atri, Ester Alvino, Maurizio Previati, Brian J. Nickoloff, Carlo M. Croce, Stefano Volinia
Article
Oncology
Cristina Cristofoletti, Antonella Bresin, Mario Picozza, Maria Cristina Picchio, Francesca Monzo, Mauro Helmer Citterich, Francesca Passarelli, Alessandra Frezzolini, Enrico Scala, Alessandro Monopoli, Maria Cantonetti, Roberto Benucci, Stefania D'Atri, Elisabetta Caprini, Giandomenico Russo, Maria Grazia Narducci
Article
Oncology
Simona Caporali, Adriana Amaro, Lauretta Levati, Ester Alvino, Pedro Miguel Lacal, Simona Mastroeni, Federica Ruffini, Laura Bonmassar, Gian Carlo Antonini Cappellini, Nadia Felli, Alessandra Care, Ulrich Pfeffer, Stefania D'Atri
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2019)
Article
Biochemistry & Molecular Biology
Chiara Platella, Umberto Raucci, Nadia Rega, Stefania D'Atri, Lauretta Levati, Giovanni N. Roviello, Maria Pia Fuggetta, Domenica Musumeci, Daniela Montesarchio
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2020)
Review
Biochemistry & Molecular Biology
Cristina Maria Failla, Maria Luigia Carbone, Cristina Fortes, Gianluca Pagnanelli, Stefania D'Atri
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2019)
Article
Cell Biology
Maria Grazia Atzori, Claudia Ceci, Federica Ruffini, Mauro Trapani, Maria Luisa Barbaccia, Lucio Tentori, Stefania D'Atri, Pedro Miguel Lacal, Grazia Graziani
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2020)
Article
Pharmacology & Pharmacy
Pedro Miguel Lacal, Maria Grazia Atzori, Federica Ruffini, Manuel Scimeca, Elena Bonanno, Rosella Cicconi, Maurizio Mattei, Roberta Bernardini, Stefania D'Atri, Lucio Tentori, Grazia Graziani
PHARMACOLOGICAL RESEARCH
(2020)
Article
Immunology
Maria Grazia Narducci, Anna Tosi, Alessandra Frezzolini, Enrico Scala, Francesca Passarelli, Laura Bonmassar, Alessandro Monopoli, Maria Pina Accetturi, Maria Cantonetti, Gian Carlo Antonini Cappellini, Federica De Galitiis, Antonio Rosato, Mario Picozza, Giandomenico Russo, Stefania D'Atri
FRONTIERS IN IMMUNOLOGY
(2020)
Article
Biochemistry & Molecular Biology
Claudio Tabolacci, Martina Cordella, Sabrina Mariotti, Stefania Rossi, Cinzia Senatore, Carla Lintas, Lauretta Levati, Daniela D'Arcangelo, Antonio Facchiano, Stefania D'Atri, Roberto Nisini, Francesco Facchiano
Summary: The study focused on secretome profiling of melanoma cells sensitive or resistant to the BRAFi vemurafenib, finding that vemurafenib-resistant melanoma cells can influence dendritic cell maturation and produce higher levels of pro-inflammatory cytokines. Proteomic and cytokine/chemokine secretion analyses suggest a possible involvement of the proteasome pathway in BRAFi resistance, with BRAFi-resistant cells displaying a more aggressive phenotype and increased production of specific proteins. Plasma levels of CD147/basigin and MMP-2 were observed to increase in melanoma patients at the time of treatment failure, supporting the hypothesis that CD147/basigin might play a role in BRAFi resistance.
Article
Oncology
Sofia Verkhovskaia, Francesca Romana Di Pietro, Simona Mastroeni, Maria Luigia Carbone, Damiano Abeni, Roberto Morese, Francesca Maria Morelli, Stefania D'Atri, Paolo Marchetti, Federica De Galitiis, Cristina Maria Failla, Cristina Fortes
Summary: The study found that the onset of vitiligo-like leukoderma during melanoma treatment could be a marker of favorable outcome and an independent predictor factor for longer duration of clinical benefits in patients treated with immune checkpoint inhibitors.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Anna Tosi, Lavinia Nardinocchi, Maria Luigia Carbone, Lorena Capriotti, Elena Pagani, Simona Mastroeni, Cristina Fortes, Fernanda Scopelliti, Caterina Cattani, Francesca Passarelli, Antonio Rosato, Stefania D'Atri, Cristina Maria Failla, Andrea Cavani
Summary: The study found that in cutaneous melanoma, there is a lower percentage of Th17 lymphocytes compared to basal cell carcinomas, and TIL clones could not differentiate into the Th17 phenotype in vitro. The presence of Th17 cells did not correlate with patient characteristics, but a lower amount was observed in samples from female donors. The expression of placenta growth factor by melanoma cells may be associated with the presence of Th17 lymphocytes.
Article
Dermatology
Mario Picozza, Cristina Cristofoletti, Antonella Bresin, Martina Fioretti, Manolo Sambucci, Enrico Scala, Alessandro Monopoli, Maria Cantonetti, Maria Antonietta Pilla, Maria Pina Accetturi, Giovanna Borsellino, Stefania D'Atri, Elisabetta Caprini, Giandomenico Russo, Maria Grazia Narducci
Summary: Sezary syndrome (SS) is a rare and aggressive variant of cutaneous T-cell lymphoma. This study investigated the expression and function of immune checkpoint molecule CD39 in a large cohort of SS patients and found that the expression level of CD39 is controlled by a genetic variation. Higher expression of CD39 was associated with a better prognosis in SS patients. Inhibition of CD39 enhanced SS cell viability and IL-2 production, suggesting caution in the use of therapeutic inhibitors of CD39 for SS treatment.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2022)
Article
Oncology
Lauretta Levati, Cristian Bassi, Simona Mastroeni, Laura Lupini, Gian Carlo Antonini Cappellini, Laura Bonmassar, Ester Alvino, Simona Caporali, Pedro Miguel Lacal, Maria Grazia Narducci, Ivan Molineris, Federica De Galitiis, Massimo Negrini, Giandomenico Russo, Stefania D'Atri
Summary: The study investigated whether circulating miRNAs could serve as biomarkers for clinical outcomes in patients receiving targeted therapy. The results suggest that circulating miR-1246 and miR-485-3p could be valuable biomarkers for identifying melanoma patients most likely to be resistant to targeted therapy or with a poor prognosis.
Article
Biochemistry & Molecular Biology
Claudio Tabolacci, Deborah Giordano, Stefania Rossi, Martina Cordella, Daniela D'Arcangelo, Federica Moschella, Stefania D'Atri, Mauro Biffoni, Angelo Facchiano, Francesco Facchiano
Summary: The study identified DLD as a potential target for overcoming vemurafenib resistance in melanoma cells, through proteomic and structural investigations on resistant sublines.